AstraZeneca:
・・・
※SOSEI：AstraZenecaから12百万米ドルのマイルストンを受領。2018年3月期に計上。各種がんに対するAZD4635(HTL-1071)の開発で重要なマイルストン達成。前臨床試験結果発表。(2017/4/5)
※SOSEI：AstraZenecaとの共同研究により、疼痛・がん・炎症性疾患領域における創薬研究を進展させる新たな知見を得る。Nature掲載。PAR2に作用する低分子を有力なリード化合物にまで前進。(2017/4/27)
※SOSE決算説明会：Wave1のパイプラインが中期臨床開発段階へと進展："アデノシンA2AのPh1a 読み出し：2017年後半ごろ"。(2017/5/12)
※ClinicalTrials: A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies. "Changes, Estimated Study Completion Date: 2017/10/12→2017/11/9" (2017/7/18update)
※AstraZeneca Q2 2017: AZD4635 (A2AR): Solid tumours and Non-Small Cell Lung Cancer: Phase 1: "Data Anticipated: 2018" (2017/7/27)
※Heptares: Corporate Overview September 2017: Wave 1 Partnered Pipeline: Progression 2017-2019: A2A Antagonist(AstraZeneca: AZD4635): "Phase 1 Trial Results". (2017/9/27up)
※ClinicalTrials: A Phase 1, Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies. "Study Completion Date: 2017/11/9(P1a)". (2017/10/18update)
※SOSEI第2四半期決算説明会：AD4635のPh.1の進捗は良好。年内に複数のがん種を対象としたIMFINZIとの併用及び単剤療法のPh1b拡張コホート試験への移行を予定。(2017/11/9)
※AstraZeneca Q3 2017: AZD4635 (A2AR): Solid Tumours and Non-Small Cell Lung Cancer: Phase 1: "Study Data Anticipated: 2018". (2017/11/9)
※国際特許出願(AstraZeneca)：Inhibitors of Protease-Activated Receptor-2 (PAR-2). (Inventors: AstraZeneca R&D & Heptares). (2017/11/16公開)
※ClinicalTrials: AZD4635, Phase 1, Estimated Study Completion Change: 2017/11/9(P1a)→"2019/8/23(P1b: Expansion Cohorts) ", Number of Patients Change: 51→"156". (2017/11/29update)
※ClinicalTrials: Phase 1b/2, MEDI9447 EGFRm NSCLC Novel Combination Study(MEDI9447 with Osimertinib or AZD4635, AZD4635 with MEDI9447): Start[Anticipated]: "2018/2/9". (2017/12/21up)
※ClinicalTrials: AZD4635, Phase 1 Expansion Cohorts, Estimated Study Completion Change: 2019/8/23→"2019/8/13". "Phase 1b Expansion Cohorts Protocol" Change. (1/4update)
※SAGE Journals: "Agonists and Antagonists of Protease-Activated Receptor 2 (PAR-2) Discovered within a DNA-Encoded Chemical Library Using Mutational Stabilization of the Target." (1/9up)
※ClinicalTrials: AZD4635, Phase 1 Expansion Cohorts, "Description, Interventions" Change. "Locations Add: New York [Not yet recruiting], North Carolina [Recruiting]". (1/17updat)